These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4212699)

  • 1. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 3. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
    Vardy J; Rabey JM; Streifler M
    Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233
    [No Abstract]   [Full Text] [Related]  

  • 7. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 9. A new selective suicide inhibitor of peripheral DOPA decarboxylase.
    Wajsbort J; Youdim MB
    Adv Neurol; 1984; 40():251-8. PubMed ID: 6364729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
    Namba S; Ishimitsu H; Nakasone S
    No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
    [No Abstract]   [Full Text] [Related]  

  • 11. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K; Ho YM
    Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 14. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 16. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Revision of the treatment strategy in Parkinson disease].
    Staal-Schreinemachers AL; Wesseling H; Lakke JP
    Ned Tijdschr Geneeskd; 1986 May; 130(20):914-8. PubMed ID: 3724865
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Nervenarzt; 1977 Apr; 48(4):205-10. PubMed ID: 404579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.